Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Moderna announced July 10 that the FDA had fully approved its Spikevax COVID vaccine for kids ages 6 months through 11 years ...

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

Notably, Pfizer's Comirnaty COVID vaccine is still approved or authorized for people 6 months of age and older without any restrictions based on risk factors for COVID — at least for now. But the FDA ...